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Abstract: Hsp90’s vital role in tumour survival and progression, together with its highly 
inducible expression profile in gliomas and its absence in normal tissue and cell lines 
validates it as a therapeutic target for glioma. Hsp90 was downregulated using the  
post-transcriptional RNAi strategy (sihsp90) and a post-translational inhibitor, the 
benzoquinone antibiotic 17-AAG. Glioblastoma U87-MG and normal human astrocyte 
SVGp12 were treated with sihsp90, 17-AAG and concurrent sihsp90/17-AAG 
(combined treatment). Both Hsp90 gene silencing and the protein inhibitor approaches 
resulted in a dramatic reduction in cell viability. Results showed that sihsp90, 17-AAG 
and a combination of sihsp90/17-AAG, reduced cell viability by 27%, 75% and 88%  
(p < 0.001), respectively, after 72 h. hsp90 mRNA copy numbers were downregulated  
by 65%, 90% and 99% after 72 h treatment with sihsp90, 17-AAG and sihsp90/17-AAG, 
respectively. The relationship between Hsp90 protein expression and its client Akt  
kinase activity levels were monitored following treatment with sihsp90, 17-AAG and 
sihsp90/17-AAG. Akt kinase activity was downregulated as a direct consequence of 
Hsp90 inhibition. Both Hsp90 and Akt kinase levels were significantly downregulated 
after 72 h. Although, 17-AAG when used as a single agent reduces the Hsp90 protein and 
the Akt kinase levels, the efficacy demonstrated by combinatorial treatment was found to 
be far more effective. Combination treatment reduced the Hsp90 protein and Akt kinase 
levels to 4.3% and 43%, respectively, after 72 h. hsp90 mRNA expression detected in 
SVGp12 was negligible compared to U87-MG, also, the combination treatment did not 
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compromise the normal cell viability. Taking into account the role of Hsp90 in tumour 
progression and the involvement of Akt kinase in cell signalling and the anti-apoptotic 
pathways in tumours, this double targets treatment infers a novel therapeutic strategy. 
Keywords: sihsp90; 17-AAG; glioblastoma; Hsp90; Akt kinase; combinational treatment 
 
1. Introduction 
Glioblastoma multiforme (GBM) is the most common malignant form of glioma, accounting for 
approximately 60–70% of all glioma cases and characterised by metastatic growth, malicious invasion 
and poor prognosis [1,2]. The current treatment for GBM consists of surgical removal of the tumour, 
followed by radiotherapy and concomitant use of the chemotherapeutic alkylating drug temozolomide 
(as recommended by The National Institute of Health and Clinical Excellence), which confers a 
survival period of 12–15 months [3]. Due to the modest effects of conventional treatment therapies, 
there is an urgent need for more effective ones. 
The molecular chaperone heat shock protein 90 (Hsp90) has recently emerged as a vital target for 
cancer therapy. Hsp90 accounts for 1–2% of total protein in normal cells, which under stress 
conditions increases to 4–6% [4,5]. Hsp90 is upregulated in various human tumours where stress is 
prevalent, which may reflect the ability of malignant cells to maintain homeostasis in noxious 
environments [6,7]. Hsp90 binds to an array of client proteins, many of which are involved in 
apoptosis, cell survival and growth pathways [8]. Many of these client proteins are mutated or 
overexpressed in GBM [1] and therefore, inhibiting Hsp90 protein or its inducible component Hsp90, 
could disrupt the oncogenic signalling pathways. Hsp90 silencing can be achieved using the 
benzoquinone antibiotic 17-allylamino-17-demethoxygeldanamycin (17-AAG) which is an Hsp90 
inhibitor [9] and RNA interference (RNAi) using small interfering RNA (siRNA) [10]. 
17-AAG promotes growth inhibition in a number of cell lines, including gliomas, as well as 
antitumour activity in vivo and in preclinical models [11-15]. 17-AAG binds to the N-terminal domain 
of Hsp90 consequently inducing proteasomal degradation of its client proteins [16-18]. The 
combinatorial effect of 17-AAG on multiple signal transduction pathways involved in proliferation and 
survival, makes 17-AAG an ideal candidate for cancer therapy in GBM whose etiology is diverse. 
Moreover, the lipophilic nature of this drug allows easy access through blood brain barrier [1], and 
thus has a potential therapeutic value in GBM. 
In humans, there are two major isoforms of Hsp90, namely Hsp90 and Hsp90β [19]. Although, 
Hsp90 levels in normal cells is lower compared to Hsp90β [19], Hsp90 expression is highly 
inducible to stressful stimuli such as heat shock, alcohol, heavy metals, oxidative stress and osmotic 
pressure changes, predominant in tumours [20]. In contrast, Hsp90β is thought to be constitutively 
expressed [21]. The high expression levels of Hsp90 has been associated with tumour progression, 
enhanced cell cycle regulation and induced cell signalling via tyrosine kinases [22]. A previous study 
in our laboratory showed high levels of both Hsp90 mRNA and protein expression in glioma cell 
lines and tissues in contrast to normal counterparts [23]. Therefore, silencing hsp90 can be a potential 
treatment strategy for GBM. The RNAi potential in gene therapy has been confirmed by several 
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preclinical studies performed in the treatment of mammalian tumours [24-26]. siRNAs have emerged 
as an effective therapeutic strategy to silence disease genes, whereby it interferes with the translation 
of almost any mRNA [27]. Recently, we showed that three siRNA constructs target-specific to the 
human hsp90 gene significantly reduced hsp90 expression after 48 h [28]. Furthermore, the glioma 
cell lines treated with a combination of TMZ and siRNA, showed enhanced chemosensitivity to TMZ 
by a 13-fold reduction in the concentration of TMZ required in order to achieve the same cytotoxic 
effects as TMZ alone [28]. 
Clinical studies to date have shown only modest activity with molecular agents directed at single 
targets, due to coactivation of multiple tyrosine kinases and the presence of redundant signalling 
pathways [29]. Given the ability of 17-AAG to target several signalling pathways in GBM, we 
assessed its effects on tumour growth and survival, both as a single agent and in combination with 
siRNA (sihsp90). This investigation aimed at downregulating Hsp90 mRNA and protein levels 
utilizing 17-AAG, siRNA and a combination of 17-AAG/sihsp90. The efficacy and the ability of 
siRNA to synergise with 17-AAG and inhibit tumour growth was determined by measuring gene 
expression and protein levels. The Akt kinase protein activity, a client protein of Hsp90 widely known 
for its involvement in anti-apoptotic pathway [1], was also monitored. 
2. Results and Discussion 
2.1. Combinatorial Assays with 17-AAG and sihsp90 Inhibits Tumour Growth in U87-MG but Does 
not Affect SVGp12 Cell Viability 
To determine the cell viability, U87-MG and SVGp12 cells were treated with 17-AAG and 
sihsp90 simultaneously with concurrent combinatorial assay. Both the gene silencing and protein 
inhibitor approaches showed dramatic reduction in cell viability in U87-MG (Figure 1A). Data showed 
that sihsp90, 17-AAG and combination of sihsp90/17-AAG reduced cell viability by 27%, 75% and 
88% after 72 h, respectively. Cytotoxic effects of 17-AAG, as a single agent, far exceeded the 
cytotoxic effects shown by sihsp90 at either 48 or 72 h. 17-AAG restricted tumour growth to 51% 
and 25% and sihsp90 treatment impaired tumour growth to 89% and 73% after 48 h and 72 h, 
respectively. To determine the therapeutic potential of this combination treatment, normal astrocyte 
cell line SVGp12 was treated with sihsp90 and 17-AAG for 48 h and 72 h (Figure 1B). Neither 
treatments significantly reduced SVGp12 cell viability after 48 h or 72 h thus demonstrating the 
tumour-specific targeting of this combination treatment. 
2.2. sihsp90 Synergize with 17-AAG Treatment in U87-MG Cell Line 
The ability of sihsp90 to synergize with 17-AAG in U87-MG was examined. The efficacy of the 
concurrent assay with 17-AAG and sihsp90 was assessed using interaction ratios generated by a ratio 
of the observed growth inhibition following treatment with both compounds versus growth inhibition 
using either compound independently. A ratio of 1 indicates additive growth inhibition, a ratio greater 
than 1 demonstrates synergistic growth inhibition, while a ratio less than 1 suggests subadditive effects 
on growth inhibition [1]. The interaction ratio calculated for concurrent treatments in this study is 
listed in Table 1. The results indicate that sihsp90 can synergize with 17-AAG and enhance treatment 
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efficacy in glioblastoma. Upon statistical analysis, the concurrent treatment with 17-AAG and 
sihsp90 showed significant reduction in cell viability after 48 h and 72 h as compared to either 
treatment acting individually. 
Figure 1. 17-AAG and sihsp90 effect on cell viability in vitro. Cell viability was 
monitored for cells treated with 17-AAG and sihsp90 after 48 h and 72 h in (A) U87-MG 
and (B) SVGp12. Control represent untreated cells, sihsp90 represent cells treated with 
hsp90 specific siRNA. sihsp90 + 17-AAG represents concurrent assays where the cells 
were treated with 17-AAG and sihsp90 for either 48 h or 72 h. * p ≤ 0.05 and ** p ≤ 0.001 
were considered statistically significant (Data values are mean ± SD, n = 3). 
 
Table 1. sihsp90 synergizes with 17-AAG enhancing chemosensitivity in U87-MG. The 
efficacy of the concurrent assay with 17-AAG and sihsp90 was assessed using interaction 
ratios generated by a ratio of the observed growth inhibition following treatment with both 
compounds versus growth inhibition using either compound independently. The data 
values are mean ± SD, n = 3. 
Interaction Ratio sihsp90 17-AAG 
after 48 h 4.62 ± 1.35 1.05 ± 0.11 
after 72 h 3.28 ± 0.19 1.18 ± 0.29 
2.3. Silencing hsp90 in Vitro with sihsp90 
In order to assess the efficiency of silencing hsp90, U87-MG cells were treated with 17-AAG, 
sihsp90 or combination of sihsp90/17-AAG to measure hsp90 and GAPDH mRNA expression 
using qRT-PCR. Cells transfected with sihsp90 alone reduced the mRNA copy number by 96% after 
48 h, however, the mRNA copy number recovered to 65% after 72 h (Figure 2A,B). 17-AAG 
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demonstrated a successful downregulation of hsp90 expression and reduced mRNA copy numbers  
by 92% and 90% after 48 h and 72 h, respectively. A combinatorial treatment with sihsp90 and 17-AAG 
together silenced hsp90 by 99% after 48 h and 72 h. The qRT-PCR results were also validated by 
agarose gel electrophoresis (Figure 2A,B). The level of hsp90 and GAPDH was also quantitated in a 
normal human astrocyte cell line SVGp12 to validate targeting hsp90, a therapeutic candidate in this 
study (Figure 3A,B). The hsp90 levels in SVGp12 demonstrated negligible though detectable levels 
of mRNA. The different treatments did not have any significant effect on transcriptional regulation  
of hsp90. 
Figure 2. The effects of 17-AAG and sihsp90 on hsp90 expression. mRNA expression 
levels of hsp90 and GAPDH in U87-MG cells treated with Hsp90 inhibitor 17-AAG 
and/or sihsp90 which targets exon 5 on the hsp90 gene were assessed by agarose gel 
electrophoresis and qRT-PCR for mRNA gene expression copy numbers after (A) 48 h and 
(B) 72 h. Lane (1) control, (2) sihsp90, (3) 17-AAG, (4) sihsp90 + 17-AAG. sihsp90 
represents cells treated with hsp90 specific siRNA. sihsp90 + 17-AAG represent 
concurrent assays where the cells were treated with 17-AAG and sihsp90 for either 48 h 
or 72 h. * p ≤ 0.05 was considered statistically significant (Data values are mean ± SD, n = 3). 
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Figure 3. hsp90 transcription level in SVGp12. mRNA expression levels of hsp90 and 
GAPDH in SVGp12 cells treated with sihsp90 which targets exon 5 on the hsp90 gene 
and/or Hsp90 inhibitor 17-AAG were assessed by agarose gel electrophoresis (A) and 
qRT-PCR (B), for mRNA gene expression copy numbers after 48 h and 72 h. Lane (1) 
control; (2) sihsp90; (3) 17-AAG; (4) sihsp90 + 17-AAG. sihsp90 represents cells 
treated with hsp90 specific siRNA. sihsp90 + 17-AAG represent concurrent assays 
where the cells were treated with 17-AAG and sihsp90 for either 48 h or 72 h. Data 
values are mean ± SD, n = 3. 
 
2.4. 17-AAG and sihsp90 Exposure Promotes Hsp90 Protein Degradation in U87-MG Cell Line 
Hsp90 protein levels were monitored by immunocytochemistry to correlate the transcription to the 
protein levels following sihsp90 and 17-AAG treatment. Figure 4 represents a sample of the stained 
cells showing a positive staining for Hsp90. Hsp90 protein levels were significantly reduced 
following independent treatment with 17-AAG and sihsp90. Most degradation of Hsp90 protein 
was observed after combinatorial treatment using 17-AAG and sihsp90 simultaneously, whereby 
only 4.3% of cells expressed Hsp90 after 48 h and 72 h (Table 2). When used as individual agents, 
sihsp90 and 17-AAG reduced Hsp90 protein levels to 30.9% and 11.4%, respectively. Based on the 
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qRT-PCR and Hsp90 protein expression data, a clear correlation between the Hsp90 mRNA and 
protein expression levels was made. 
Figure 4. Hsp90 protein level in U87-MG assessed using immunohistochemistry. The 
cells were stained with FITC conjugate secondary antibody bound to Hsp90 antigen 
(green) and propidium iodide (PI) to detect nucleus (red) at ×40 objective magnifications. 
Hsp90 was mainly located in the cell cytoplasm. 
 
Table 2. Hsp90 expression in U87-MG post 17-AAG and sihsp90 treatment. The 
Hsp90 levels were deduced as the fraction of the observed Hsp90 levels in treated 
samples relative to the total Hsp90 levels in the untreated sample using immunofluorescence 
after 48 h and 72 h. Hsp90 expression analysis using immunofluorescence was performed 
by counting 150 cells. sihsp90 represent cells treated with hsp90 specific siRNA. 
sihsp90 + 17-AAG represent concurrent assays where the cells were treated with 17-AAG 
and sihsp90 for either 48 h or 72 h. This data is typical of three independent experiments. 
* p ≤ 0.05 and ** p ≤ 0.001 were considered statistically significant. 
% Cells Expressing Hsp90 after Control sihsp90 17-AAG sihsp90 + 17-AAG 
48 h 64.3 ± 4.2 30.9 ± 2.9 ** 15.6 ± 1.4 ** 4.7 ± 1.0 ** 
72 h 65.1 ± 4.6 54.5 ± 2.7 * 11.4 ± 1.2 ** 4.3 ± 0.8 ** 
2.5. Hsp90 Inhibition Promotes Degradation of Hsp90 Client Akt/PKB Kinase in U87-MG 
To examine whether Hsp90 inhibition was accompanied by rapid loss of Akt protein, the Akt 
kinase activity was monitored in control and treated U87-MG cells using a Akt/PKB kinase activity 
assay. A combination of sihsp90 and 17-AAG reduced Akt activity to 47.3% and 43% after 48 h  
and 72 h, respectively (Figure 5). When only 17-AAG was used, it was found to reduce Akt levels  
to 63% and 61 % after 48 h and 72 h treatments. Silencing hsp90 with siRNA inactivated Akt activity 
by 41% after 48 h. However, after 72 h the Akt activity was upregulated to over 100%. The expression 
profile of Akt emulates that of Hsp90 mRNA and the protein level following sihsp90 and 17-AAG 
treatments (Figure 2 and Table 2). The results of the qRT-PCR, Hsp90 protein and Akt activity indicates 
a strong correlation between mRNA, protein and Akt expression levels in U87-MG cell line (Table 3). 
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Figure 5. Hsp90 inhibition results in loss of Akt activity in U87-MG cell line. The Akt 
activity (%) was deduced as the fraction of the observed Akt activity in treated samples 
relative to the total Akt activity in the untreated sample after 48 h (A) and 72 h (B). 
sihsp90 represent cells treated with hsp90 specific siRNA. sihsp90 + 17-AAG 
represent concurrent assays where the cells were treated with sihsp90 and 17-AAG for 
either 48 h or 72 h. * p ≤ 0.05 and ** p ≤ 0.001 were considered statistically significant 
(Data values are mean ± SD, n = 3). 
 
Table 3. The correlation profile between Hsp90 expression at mRNA and protein with 
Akt activity and cell viability in U87-MG cell line. 
 
Hsp90 mRNA/100 ng 
Cells Extract 
(1 × 106 Cells) 
% Cells Expressing 
Hsp90 
% Akt/PKB 
Kinase Activity 
% Cell Viability 
Control 
48 h 6,915 ± 863 64.3 ± 4.2 100 ± 3.5 100 ± 5 
72 h 6,919 ± 867 65.1 ± 4.6 100 ± 2.5 100 ± 4.5 
siRNA 
48 h 265 ± 95 30.9 ± 2.9 59.3 ± 3.8 89 ± 3 
72 h 2,420 ± 967 54.5 ± 2.7 105.1 ± 0.79 73 ± 1.5 
17-AAG 
48 h 269 ± 107 15.6 ± 1.4 62.7 ± 0.48 51 ± 3.5 
72 h 694 ± 234 11.4 ± 1.2 61.1 ± 3.4 24.8 ± 1.9 
siRNA/17AAG  
48 h 48 ± 7 4.7 ± 1.0 47.3 ± 0.91 48 ± 9 
72 h 40 ± 4.5 4.3 ± 0.8 43 ± 1.28 11.3 ± 1.5 
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2.6. Discussion 
In tumours, the induced Hsp90 expression is responsible for the addiction of tumour cells to 
multiple signalling pathways where Hsp90 clients play an oncogenic role [30]. Furthermore, the Hsp90 
conformation in tumours has demonstrated a higher binding affinity for 17-AAG, compared to the 
native Hsp90 in normal cells [31]. Although, normal proteins have limited requirement for Hsp90 
assistance, tumours are highly dependent on Hsp90 chaperone activity to cope with the lethal 
conditions prevalent in tumours and to regulate mutated and functionally deregulated proteins [32]. In 
the present study, the anti-tumour effect of 17-AAG and sihsp90 in U87-MG and not SVGp12 cells 
validates the reliance of brain tumours on Hsp90 for tumour growth and progression. In addition, the 
combinatorial therapy of 17-AAG and sihsp90 may have therapeutic potential for GBM, taking into 
consideration, the ability of 17-AAG to target-specifically bind to tumour cells at a low concentration 
compared to conventional therapeutic drugs and the increasing therapeutic potential of RNAi 
technique for gene therapy [28,33]. 
In order to assess quantitative gene silencing in GBM using sihsp90 and 17-AAG, hsp90 and 
GAPDH (control) mRNA expressions were measured using qRT-PCR. Results showed that a 
combination of 17-AAG and sihsp90 significantly reduced hsp90 copy numbers by 99% in GBM 
after 48 h and 72 h. Sequence specific interactions between the siRNA and target mRNA are essential 
for RNAi functionality, and the target site recognition relies on the molecular mechanism of RNA-RNA 
interactions [34]. Our data reveals a therapeutic potential of the siRNA used in this study for glioma 
therapy. To further support our findings, the cytotoxic effects of sihsp90 and 17-AAG on a normal 
human astrocyte cell line SVGp12 was investigated. The SVGp12 cell viability was not significantly 
affected showing less than 5% reduction in viable cells after 48 h and 72 h which clearly demonstrated 
selective tumour cell targeting over normal cells. These findings correlate with previous studies in our 
laboratory, which shows that hsp90 expression is highly induced in U87-MG, compared to normal 
counterpart [23]. Since hsp90 was transcribed at basal level in SVGp12 and other normal brain cell 
lines [23], there was no need to carry out further investigations to utilizing these cell lines. 
The transcription of human hsp90 gene is regulated by the 5' upstream promoter sequences 
bearing the heat shock elements (HSEs) known to regulate gene expression of hsp90 [19]. The heat 
shock factor 1 (HSF1) binds to the HSEs and marks the initiation of hsp90 gene transcription. Under 
normal conditions, HSF1 is bound to cytosolic Hsp90 and Hsp70 and hence avoids transcription of 
heat shock genes. However, under stress, or upon inhibition of Hsp90, the Hsp90 chaperone refolds 
partially denatured client proteins which liberates HSF1, consequently resulting in its translocation to 
the nucleus where it initiates transcription of hsp90 gene [35]. This negative feedback mechanism may 
be a continued source of Hsp90 in tumour cells treated with 17-AAG or sihsp90, which may be 
responsible for tumour survival even after 72 h. In this study, we targeted the inducible isoform 
hsp90 mRNA using sihsp90 and Hsp90 protein using 17-AAG with an aim to achieve maximum 
Hsp90 inhibition. The results from this study indicate that the enhanced synergistic cytotoxicity 
observed in glioblastoma U87-MG and not in normal astrocyte cell line SVGp12, using combination 
treatment with sihsp90/17-AAG, may be due to a greater degree of Hsp90 inhibition. Our results also 
indicate that the normal astrocytes SVGp12 are not dependent on Hsp90 for cell growth and survival. 
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The fundamental role of Hsp90 in tumour invasion and cell cycle has previously been  
investigated [36]. However, altered hsp90 expression post 17-AAG treatment has not been studied in 
U87-MG cells. Nevertheless, a study by Clarke et al. investigating hsp90 gene expression in colon 
adenocarcinoma cell lines showed that the hsp90 expression in HCT116 (human colon cancer cells) 
following 17-AAG treatment was induced [37]. The same treatment on HT29 (human colon cancer 
grade II cell line) had no influence on hsp90 mRNA levels, suggesting that the post-transcriptional 
regulation of hsp90 after 17-AAG treatment was cell line dependent [37]. In GBM, 17-AAG was 
observed to downregulate hsp90 mRNA expression after 48 h and 72 h which correlates with its 
cytotoxic effects in vitro. 
Hsp90 expression in tumours is 2 to 10-fold higher as compared to its basal expression in normal 
counterparts [38]. In addition to chaperoning mutated and deregulated client proteins, Hsp90 is of 
critical importance in tumour survival and progression. Theoretically, silencing hsp90 gene with 
sihsp90 should lead to tumour demise. The overall results from this study reveal non-complementarity 
between the cell viability and qRT-PCR data after sihsp90 treatment. Although, hsp90 mRNA 
expression was reduced by 96%, the cell viability was barely affected at 90%. hsp90 gene silencing 
was effective up to 48 h using sihsp90, however, sihsp90 vulnerability to metabolism within the cell 
and its inability to duplicate [39], ultimately lead to hsp90 resurgence after 72 h. In contrast, the 
Hsp90 protein half-life of 36 h may suggest that the efficacy of hsp90 silencing on cell viability was 
modest after 48 h and 72 h, owing to the downstream regulation of anti-apoptotic clientele by Hsp90 [40]. 
The Hsp90 expression after treatment with 17-AAG and sihsp90 were measured by 
immunocytochemistry. The Hsp90 peptide was detected using FITC-conjugated secondary antibodies, 
taking into consideration the intensity, contrast and sharpness of the image. The Hsp90 protein 
expression profiles showed a distinct correlation with the hsp90 mRNA expression in U87-MG 
which strongly suggests that the regulation of Hsp90 occurs not only at post-translational level as 
proposed by previous observations [30], but also under transcriptional control. 
The Hsp90 chaperone plays a vital role at maintaining Akt stability [40]. The involvement of Akt 
kinase in deregulated signalling pathways which facilitates tumour progression, survival and invasion, 
has been well documented [41]. Previous studies have demonstrated severe inhibition of Akt-dependent 
anti-apoptotic signalling pathways upon 17-AAG administration in gastric cancers, urinary bladder 
cancer and osteosarcoma [30,42,43]. To determine whether Hsp90 inhibition/silencing disturbed Akt 
levels in U87-MG, Akt kinase activity was measured using a Akt/PKB kinase activity kit. The present 
study showed downregulation of Akt kinase levels post 17-AAG and sihsp90 treatment which 
decisively contributes to the cytotoxic potencies of 17-AAG and sihsp90 after 48 h and 72 h. The 
decrease in cell viability observed in U87-MG cells may be attributed to the 17-AAG-dependent 
inhibition of Akt activity in addition to the sihsp90-mediated hsp90 downregulation which 
counteracts the tumour survival response of hsp90 upregulation [22], eventually leading to Hsp90 
depletion and apoptosis. It has been previously demonstrated that depletion of hsp90β by siRNA can 
induce apoptosis in multiple myeloma [44], which may suggest cooperating anti-apoptotic properties 
for Hsp90 and Hsp90β. In this study, downregulation of Hsp90 with sihsp90 was insufficient in 
suppressing Akt activity in U87-MG after 72 h, possibly due to the anti-apoptotic role of Hsp90β via 
association with Bcl-2 leading to caspase inactivation and to cell survival [45]. Also, it could be 
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attributed to the inability of siRNA to duplicate, reducing silencing efficacy through cell division [39]. 
This may suggest why Akt levels recovered after 72 h following sihsp90 treatment. 
Although, 17-AAG and sihsp90 triggered Akt degradation, interestingly, the most significant Akt 
suppression achieved was relatively higher than the corresponding Hsp90 levels. This may suggest 
that crucial components of the growth and survival signalling pathways, such as the Akt kinase, are not 
regulated by only Hsp90 chaperone. Indeed, upregulation of Hsp70 following Hsp90 inhibition using 
17-AAG has been previously reported in prostate, cervical, and human colon tumours [37,46]. 
Furthermore, a recent proteomic study from our laboratory also showed the induced Hsp70 levels post 
17-AAG exposure in glioblastoma cells (data unpublished). Thus, even though 17-AAG and sihsp90 
inhibited Hsp90 levels in GBM, compensatory upregulation of Hsp70 may have proven to exhibit 
regulatory effects on Akt [47]. The Akt activity was reduced by 2.3-fold with the dual combination 
treatment after 72 h despite the Hsp70 compensation. This reduction of Akt activity demonstrates 
induced chemosensitivity in GBM since Hsp90 binds and protects Akt from dephosphorylation which 
is responsible for inactivation of Bcl-2 family protein Bad and caspase-9, known to be inducers of the 
intrinsic apoptosis pathway [20]. 
In our investigation, we have shown for the first time that a combination of 17-AAG and siRNA 
targeting hsp90 significantly suppresses GBM growth after 48 h and 72 h in vitro, clearly evident 
from the reduced Akt activity. This suggests that mutated proteins in GBM may have enhanced 
Hsp90 binding affinity and are more sensitive to Hsp90 inhibition [23]. Despite its anti-tumour 
activity in GBM, RNAi efficiency using siRNA is very limited in vivo, mainly due to siRNA 
degradation by nucleases, non-specific immune stimulation and poor cellular uptake [27,48,49]. 
However, intracellular delivery of biologically active siRNA has been successfully achieved using 
delivery systems [50,51]. The on-going work in our laboratory aims to address these limitations and to 
enhance cellular siRNA uptake, serum stability and pharmacokinetics using cell penetrating peptides. 
3. Experimental Section 
3.1. Cell Culture 
The human brain tumour cell line U87-MG (glioblastoma multiforme) and human normal astrocyte 
cell line SVGp12 were purchased from European Collection of Cell Cultures (ECACC) and the 
American Type Culture Collection (ATCC), respectively. Both U87-MG and SVGp12 were cultured 
in Eagle’s minimum essential medium (EMEM) (Lonza). The culture medium was supplemented with 
2 mM L-glutamine (Sigma), 10% FBS (Gibco-BRL, Paisley, UK), 1% (v/v) non-essential amino acids 
and 1 mM sodium pyruvate. The cells were incubated at 37 °C in a humidified 5% CO2 incubator. 
3.2. Drug Preparation and Treatment 
17-AAG was obtained from InvivoGen (UK) and was reconstituted in DMSO to give a stock 
concentration of 2 mM. The glioblastoma U87-MG was treated with increasing concentrations of 17-AAG 
and a 50% inhibitory concentration (IC50) of 225 nM was determined (Figure 6). The stock solution 
was diluted in culture medium to achieve a final working concentration of 225 nM which was added to 
the cells and incubated for 48 h and/or 72 h. 
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Figure 6. The IC50 for the Hsp90 inhibitor 17-AAG was assessed by increasing concentration 
of 17-AAG (0–0.5 µM). The data values are mean ± SD, n = 3. 
 
3.3. sihsp90 Electroporation and Transfection 
The Silencer® Pre-designed siRNA used for transfections were obtained from Ambion (UK).  
The siRNA sequences consisted of 21-nt and targets Hsp90AA1 gene with sense strand:  
5' CGUGAUAAAGAAGUAAGCGtt 3' (NM_005348.3) and antisense: 5' CGCUUACUUCUUUAUC-
ACGtt 3'. The annealed sihsp90 was resuspended in nuclease-free water to achieve a stock 
concentration of 100 µM which was further diluted to 50 µM working concentration prior to use. 
The electroporation condition for sihsp90 used in this study has previously been optimised in our 
laboratory [28]. The siRNA transfections were carried out using the siPORT™ siRNA Electroporation 
Kit according to the manufacturer’s instructions (Ambion, UK). Bio-Rad gene pulser Xcell was used 
for electroporation. Following transfection cells were transferred to a 25 cm2 tissue culture flask with 
pre-warmed medium and incubated for up to 72 h. For concurrent combinatorial assays involving 
sihsp90 and 17-AAG, 17-AAG (225 nM) was added to the pre-warmed medium prior to transferring 
cells into the flask. 
3.4. Cell Viability Assay 
The cell viability was assessed using CellTiter-Glo® Luminescent cell viability assay (Promega, 
UK) [28]. Cells were seeded in a 96-well plate 24 h prior to treatment with sihsp90, 17-AAG and/or 
combination of 17-AAG/sihsp90. The luminescent signal was recorded using Tecan GENios Pro® 
(Tecan, Austria). 
3.5. mRNA Isolation, Reverse Transcription and qRT-PCR 
An average of 1 ρg/cell of mRNA was extracted from cells using mRNA isolation kit (Roche 
Diagnostics, UK) according to manufacturer’s instructions. Isolated mRNA (100 ng) was transcribed 
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to cDNA using a First Strand cDNA Synthesis Kit (Roche Diagnostics, UK) which was used as a 
template for PCR. Quantitative Real Time PCR (qRT-PCR) was used to evaluate the expression of 
hsp90 and GAPDH (a housekeeping gene) in control and treated U87-MG cells. Primers were 
obtained from TIB MOLBIOL, Germany. The primer sequence and length of the amplicons were: 
hsp90 (189 bp) sense: 5' tctggaagatccccagacac 3', antisense: 5' agtcatccctcagccagaga 3', and  
GAPDH (238 bp) sense: 5' gagtcaacggatttggtcgt 3', antisense: 5' ttgattttggagggatctcg 3'. qRT-PCR was 
performed in triplicate using Fast Start DNA master PLUS SYBR Green 1 (Roche Diagnostics, UK) in 
a LightCycler real-time PCR detection system (Roche Diagnostics, Germany) as described previously [23]. 
Quantitative amplification was monitored by the level of fluorescence reflecting the cycle number at 
the detection threshold (crossing point) using a standard curve [23]. 
3.6. Protein Extraction and Quantitative Assessment 
Following treatment, the cells were collected and then lysed using CelLytic™ M Cell Lysis 
Reagent (Sigma, UK) supplemented with a protease inhibitor cocktail [52]. Total protein was isolated 
by centrifugation at 13,000 rpm for 15 min to remove cell debris. The protein concentration was 
determined using the Bradford protein assay. 
3.7. Immunocytochemistry 
Cells were seeded on culture slides in 6 well plates 24 h prior to treatment. Following treatment the 
cells were fixed with 4% paraformaldehyde, washed three times with warm PBS and subsequently 
permeablised with 0.3% Triton X-100 at room temperature for 7 min. The cells were washed three 
times with warm PBS and incubated in blocking solution followed by 1 h of incubating in primary 
monoclonal antibody against Hsp90 antigen (Cambridge Bioscience, UK). After incubating the cells, 
they were washed and exposed to a secondary antibody (goat anti-rat IgG FITC) for 1 h with gentle 
agitation. Finally, cells were washed and counter stained with PI (Vectashield, UK), mounted and 
fixed on slides for analysis. For each sample, a total of 150 cells were counted using Axiovert 200M 
LSM 510 laser scanning confocal microscope (Carl Zeiss Ltd, UK). Hsp90 was stained with FITC 
and the nucleus with propidium iodide (Figure 4). 
3.8. Akt/PKB Kinase Assay 
Akt/PKB kinase activity was measured using a non-radioactive Akt/PKB kinase activity assay that 
detects Akt/PKB kinase activity in the solution phase (Assay Designs, UK; Cat No. EKS-400A). Total 
protein isolated as described above and 10 µg of protein from each sample were used to perform Akt 
kinase assay according to the manufacturer’s instructions. 
3.9. Statistical Analysis 
In this study, data was analysed using the PASW Statistics 18 package using the One-Sample 
Students T-test and Paired-Sample T-test. A p value of * p ≤ 0.05 and ** p ≤ 0.001 was considered as 
statistically significant. 
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4. Conclusions 
We have demonstrated the anti-tumour effects in GBM utilizing 17-AAG and sihsp90 in vitro. 
The combinatorial treatment of 17-AAG/sihsp90 significantly downregulated Hsp90 mRNA and 
protein levels in GBM. Akt activity, a major survival kinase, was also found to be reduced. In contrast, 
neither of the treatments had a significant effect on SVGp12 cell viability. The transcriptional 
regulation of hsp90 was negligible in SVGp12. Given the role of Akt in growth signalling pathways, 
Hsp90-dependent Akt downregulation was accompanied by reduced cell viability. Thus, targeting 
Hsp90 using 17-AAG/sihsp90 may have a clinical prospect in treatment of GBM. 
Given the role of Hsp70 and Hsp90β in cell survival pathways, future work could focus at 
downregulating Hsp70 and Hsp90β using protein inhibitors and siRNA respectively, and assessing its 
tumour inhibition potential which may enhance our understanding of the complex role played by the 
chaperones in tumour survival and progression. 
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